Download
s10585-020-10046-y.pdf 308,88KB
WeightNameValue
1000 Titel
  • Assessment of incentivizing effects for cancer care frameworks
1000 Autor/in
  1. Haier, Jörg |
  2. Sleeman, Jonathan |
  3. Schäfers, Jürgen |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-17
1000 Erschienen in
1000 Quellenangabe
  • 37(4):447-450
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10585-020-10046-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238726/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Pancreatic metastasis is a rare cause for pancreas surgery and often a sign of advanced disease no chance of curative-intent treatment. However, surgery for metastasis might be a promising approach to improve patients' survival. The aim of this study was to analyze the surgical and oncological outcome after pancreatic resection of pancreatic metastasis.!##!Methods!#!This is a retrospective cohort analysis of a prospectively-managed database of patients undergoing pancreatic resection at the University of Freiburg Pancreatic Center from 2005 to 2017.!##!Results!#!In total, 29 of 1297 (2%) patients underwent pancreatic resection due to pancreatic metastasis. 20 (69%) patients showed metastasis of renal cell carcinoma (mRCC), followed by metastasis of melanoma (n = 5, 17%), colon cancer (n = 2, 7%), ovarian cancer (n = 1, 3%) and neuroendocrine tumor of small intestine (n = 1, 3%). Two (7%) patients died perioperatively. Median follow-up was 76.4 (range 21-132) months. 5-year and overall survival rates were 82% (mRCC 89% vs. non-mRCC 67%) and 70% (mRCC 78% vs. non-mRCC 57%), respectively. Patients with mRCC had shorter disease-free survival (14 vs. 22 months) than patients with other primary tumor entities.!##!Conclusion!#!Despite malignant disease, overall survival of patients after metastasectomy for pancreatic metastasis is acceptable. Better survival appears to be associated with the primary tumor entity. Further research should focus on molecular markers to elucidate the mechanisms of pancreatic metastasis to choose the suitable therapeutic approach for the individual patient.
1000 Sacherschließung
lokal Surgical Oncology
lokal Humans [MeSH]
lokal Delivery of Health Care/economics [MeSH]
lokal Oncology
lokal Editorial
lokal Hematology
lokal Cancer Care in low- and middle-income countries
lokal Cancer Research
lokal Neoplasm Metastasis/pathology [MeSH]
lokal Neoplasms/pathology [MeSH]
lokal Neoplasms/therapy [MeSH]
lokal Biomedicine, general
lokal Reimbursement, Incentive [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SGFpZXIsIErDtnJn|https://frl.publisso.de/adhoc/uri/U2xlZW1hbiwgSm9uYXRoYW4=|https://frl.publisso.de/adhoc/uri/U2Now6RmZXJzLCBKw7xyZ2Vu
1000 Hinweis
  • DeepGreen-ID: a2c2e192fd7d41249b663f713de36f4e ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Assessment of incentivizing effects for cancer care frameworks
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6468316.rdf
1000 Erstellt am 2023-11-17T15:38:57.824+0100
1000 Erstellt von 322
1000 beschreibt frl:6468316
1000 Zuletzt bearbeitet 2023-12-01T07:42:11.938+0100
1000 Objekt bearb. Fri Dec 01 07:42:11 CET 2023
1000 Vgl. frl:6468316
1000 Oai Id
  1. oai:frl.publisso.de:frl:6468316 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source